T2CURE GMBH has a total of 21 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2004. It filed its patents most often in EPO (European Patent Office), United States and Japan. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are ONYX PHARMACEUTICALS, ARCHEMIX LLC and FUWAN PTY LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 6 | |
#2 | United States | 4 | |
#3 | Japan | 3 | |
#4 | Canada | 2 | |
#5 | Hungary | 2 | |
#6 | Germany | 1 | |
#7 | Israel | 1 | |
#8 | Slovenia | 1 | |
#9 | WIPO (World Intellectual Property Organization) | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Dimmeler Stefanie | 16 |
#2 | Urbich Carmen | 10 |
#3 | Bonauer Angelika | 10 |
#4 | Zeiher Andreas M | 9 |
#5 | Zeiher Andreas | 7 |
#6 | Koyanagi Masamichi | 4 |
#7 | Andreas M Zeiher | 3 |
#8 | Carmen Urbich | 3 |
#9 | Angelika Bonauer | 3 |
#10 | Stefanie Dimmeler | 3 |
Publication | Filing date | Title |
---|---|---|
EP2138572A1 | Mesoangioblast-like cell as well as methods and uses relating thereto | |
DE102007052114A1 | Method for modulating the function, growth or differentiation of a cell |